As the leading Duchenne muscular dystrophy (DMD) charity in the UK, we aim to end Duchenne's devastating impact. We connect scientists, the pharmaceutical industry, the NHS and families to advance and accelerate medical research, while bringing everyone affected by DMD the care and support they need.
We need to go further than anyone has before to find effective treatments. This means setting our ambitions high and overcoming every barrier in our way.
We’re going to do it faster, because this generation of people living with DMD can’t wait.
The only way we can achieve this is together. We create a network of mutual support for families. We collaborate with scientists and the pharmaceutical industry, bringing them together to share knowledge. And we work with health services so that patients get the care they need.
Celebrate the 10th anniversary of the Duchenne Dash by taking on a 10 for Duchenne challenge at home, however you choose!
Find out more
Duchenne muscular dystrophy is a genetic disease which causes progressive muscle weakening from an early age.
About DMD
Join our mission to fund life-changing DMD treatments by fundraising, donating, or joining an event.
Get involved
The DMD Hub is a network of sites carrying out clinical studies for Duchenne muscular dystrophy.
Visit the DMD Hub site
Read More
The World Muscle Society has issued new advice on COVID-19 for people living with neuromuscular diseases such as DMD.
Read More
Duchenne UK has funded a three-year research project to investigate drugs that could delay muscle degeneration.
Read More
Staying active and being part of a team can have huge benefits for young people with DMD. We spoke to people in the DMD community about the sports they play and how you can get involved.
Read More
Duchenne UK and the DMD Hub are launching a new pilot project aiming to provide fair and equal access to DMD trials across the UK
Read More
Read about all we achieved with your support in 2021 in our latest impact report
Read More
Duchenne UK has launched a new mobile app that could help to save DMD patients’ lives in medical emergencies.
Read More
Duchenne UK is disappointed to announce that a project investigating the potential of montelukast, an existing anti-inflammatory drug for asthma, to treat DMD failed to show benefit in a pre-clinical study.
Read More
This week, the Joint Committee on Vaccination and Immunisation (JCVI) recommended immunosuppressed people aged 12 and over get a ‘spring booster’ of the COVID-19 vaccine six months after their most recent dose.
Read More
Sign up for the latest news on DMD research, upcoming events and ways to get involved.
